Hansoh Pharmaceutical Group Co (FRA:3KY) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3KY Hansoh Pharmaceutical Group Co Ltd FRA:3KY
86 GF Score
Price €3.57
GF Value €2.92
Valuation Modestly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co FFO?

FFO (Funds from operations) only applies to REITs.

FRA:3KY
86GF Score
Hansoh Pharmaceutical Group Co Ltd FRA:3KY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hansoh Pharmaceutical Group Co (FRA:3KY) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of €3.57 is trading 22.4% above its estimated GF Value™ of €2.92. GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for FRA:3KY:

  • FFO:
  • GF Value™: €2.92 vs. price of €3.57 (22.4% above fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the FRA:3KY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
86GF Score

Get the complete analysis for FRA:3KY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.57
Price
€2.92
GF Value